Exonics Therapeutics Finds $5M In Funding

Exonics Therapeutics, a biotech startup with research and development operations in Dallas, has raised $5M in a seed funding round, according to investor CureDuchenne Ventures. CureDuchenne said that Exonics is focused on developing gene editing technology for treating Duchenne muscular dystrophy. Exonics is based in Boston, but according to CureDuchenne is research efforts are based in Dallas. Exonics said that its technology has been licensed from the University of Texas Southwestern Medical Center (UTSW) and is based on the research of its scientific founder and chief science advisor, Eric Olson, Phd.